Shandong Buchang Pharmaceuticals (603858.SH) plans to transfer its 60% equity stake in its subsidiary Hunan Zhongce.

19:37 12/03/2026

Beijing SL Pharma (603858.SH) announces that, due to business development needs, its subsidiary Beijing SL (Guangzhou) Medical Diagnosis plans to transfer 60% of its shares in Hunan Zhongce Biological Technology Co., Ltd. ("Hunan Zhongce") to Yang Futai at a price of 1 RMB. After the completion of this transfer, Beijing SL (Guangzhou) Medical Diagnosis will no longer hold any shares in Hunan Zhongce.

Shandong Buchang Pharmaceuticals (603858.SH) announced that, due to business development needs, its subsidiary Bukang (Guangzhou) Medical Diagnostics plans to transfer 60% of its equity in Hunan Zhongce Biological Technology Co., Ltd. ("Hunan Zhongce") to Yang Futai at a price of 1 yuan. After this transfer is completed, Bukang (Guangzhou) Medical Diagnostics will no longer hold any equity in Hunan Zhongce.

Chairman of Xiamen Amoytop Biotech (688278.SH) proposed to repurchase company shares with an amount of 100 million to 200 million yuan.

FIT HON TENG (06088) announced its annual performance, with a net profit attributable to shareholders of 156 million US dollars, a year-on-year increase of 1.51%.

CHI MER LAND (00978) announced its annual performance, with a net loss attributable to shareholders of 2.201 billion yuan, an increase of 18.93% year-on-year.

Chairman of Xiamen Amoytop Biotech (688278.SH) proposed to repurchase company shares with an amount of 100 million to 200 million yuan.

FIT HON TENG (06088) announced its annual performance, with a net profit attributable to shareholders of 156 million US dollars, a year-on-year increase of 1.51%.

CHI MER LAND (00978) announced its annual performance, with a net loss attributable to shareholders of 2.201 billion yuan, an increase of 18.93% year-on-year.